Elicio Therapeutics Inc. (NASDAQ:ELTX) — Market Cap & Net Worth
Market Cap & Net Worth: Elicio Therapeutics Inc. (ELTX)
Elicio Therapeutics Inc. (NASDAQ:ELTX) has a market capitalization of $53.44 Million ($53.44 Million) as of August 8, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21663 globally and #4782 in its home market, demonstrating a 8.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elicio Therapeutics Inc.'s stock price $3.14 by its total outstanding shares 19086081 (19.09 Million). See Elicio Therapeutics Inc. capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Elicio Therapeutics Inc. Market Cap History: 2021 to 2026
Elicio Therapeutics Inc.'s market capitalization history from 2021 to 2026. Data shows change from $553.50 Million to $59.93 Million (-51.61% CAGR).
Index Memberships
Elicio Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.00% | #615 of 976 |
|
NASDAQ Composite
IXIC
|
$40.73 Trillion | 0.00% | #2072 of 3165 |
Weight: Elicio Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elicio Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elicio Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.55x
Elicio Therapeutics Inc.'s market cap is 19.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $553.50 Million | $28.31 Million | -$26.40 Million | 19.55x | N/A |
Competitor Companies of ELTX by Market Capitalization
Companies near Elicio Therapeutics Inc. in the global market cap rankings as of August 8, 2026.
Key companies related to Elicio Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #571 globally with a market cap of $47.50 Billion USD ( ₩70.08 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.03 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $772.11 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €753.80 |
| #571 | Samsung Biologics Co Ltd | KO:207940 | $47.50 Billion | ₩1514000.00 |
Elicio Therapeutics Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Elicio Therapeutics Inc.'s market cap moved from $553.50 Million to $ 59.93 Million, with a yearly change of -51.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $59.93 Million | -60.55% |
| 2025 | $151.93 Million | +56.08% |
| 2024 | $97.34 Million | -38.85% |
| 2023 | $159.18 Million | +2.71% |
| 2022 | $154.98 Million | -72.00% |
| 2021 | $553.50 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Elicio Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.44 Million USD |
| MoneyControl | $53.44 Million USD |
| MarketWatch | $53.44 Million USD |
| marketcap.company | $53.44 Million USD |
| Reuters | $53.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more